Related Experiment Videos

[Heart rate and blood pressure of sportsmarksmen in competition]

P Schmid, J Borkenstein, H Pessenhofer

Schweizerische Zeitschrift Fur Sportmedizin

|January 1, 1978

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer.

ESMO open·2026

Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N = 7914).

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Endocrine response assessment in HR-positive HER2-negative early breast cancer: concordance of local versus central Ki67 measurements in the WSG ADAPTcycle trial (n = 5292).

ESMO open·2025

See all related articles